Labarile Nunzia, Castellana Fabio, Sila Annamaria, Pesole Pasqua Letizia, Coletta Sergio, Curlo Margherita, Sardone Rodolfo, Giannelli Gianluigi, Mastronardi Mauro
Unit of Gastroenterology, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Unit of Research Methodology and Data Sciences for Population Health, National Institute of Gastroenterology IRCCS "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Vaccines (Basel). 2022 Jul 4;10(7):1077. doi: 10.3390/vaccines10071077.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has affected the entire planet. The objectives of our study were to compare responses to the vaccine (Pfizer-Biontech COMIRNATY) in a population of patients with intestinal bowel syndrome undergoing different biological therapies or conventional therapy. The study recruited 390 patients who received the first vaccination dose during the dedicated vaccination campaign for inflammatory bowel disease (IBD) patients. The inclusion criteria were a diagnosis of CD or UC and complete vaccination with the Pfizer-BioNTech COVID-19 (Comirnaty) vaccine. The exclusion criteria were other significant diseases or important therapies under way or contraindications to vaccination according to the European drug surveillance recommendations. Linear rank models were run to assess the association between the different therapies and S1/S2 antibodies at three different times. The models showed that in patients with IBD receiving Vedolizumab a significant increase in mean IgG levels was observed, independently of other therapies and confounding factors (β: 57.45, 95% CI 19.62 to 19.00). This study confirmed the complete antibody response to vaccination against COVID-19 in patients with IBD undergoing biological therapy-particularly Vedolizumab treatment-but also a reduced immune response due to concomitant steroid therapy.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染已影响到整个地球。我们研究的目的是比较接受不同生物疗法或传统疗法的肠易激综合征患者群体对疫苗（辉瑞-生物科技公司的COMIRNATY）的反应。该研究招募了390名在专门针对炎症性肠病（IBD）患者的疫苗接种活动期间接受第一剂疫苗接种的患者。纳入标准为克罗恩病（CD）或溃疡性结肠炎（UC）的诊断以及辉瑞-生物科技公司新冠病毒疫苗（Comirnaty）的全程接种。排除标准为其他重大疾病或正在进行的重要治疗，或根据欧洲药物监测建议存在疫苗接种禁忌。运行线性秩模型以评估不同疗法与三个不同时间点的S1/S2抗体之间的关联。模型显示，在接受维多珠单抗治疗的IBD患者中，观察到平均IgG水平显著升高，独立于其他疗法和混杂因素（β：57.45，95%置信区间19.62至19.00）。本研究证实了接受生物疗法（尤其是维多珠单抗治疗）的IBD患者对新冠病毒疫苗接种有完整的抗体反应，但同时由于类固醇疗法，免疫反应有所降低。
